In tablet manufacturing, carbamazepine anhydrous Form III is the preferred starting polymorph because it avoids the hydration-mediated changes in dissolution behaviour that accompany the dihydrate. A direct-compression or roller-compacted formulation with a core mass of 320–400 mg for a 200 mg label claim places the drug load between 50% and 62.5% w/w. Microcrystalline cellulose is included at 20–30% w/w to provide compactibility; croscarmellose sodium at 2–5% w/w functions as the disintegrant. Povidone K30 at 2–4% w/w may be added as a dry binder, and magnesium stearate is restricted to 0.25–0.5% w/w with a total lubrication time not exceeding 5 minutes to avoid hydrophobic coating of the API. Compression on a 45-station rotary press uses a precompression force of 4–8 kN and a main compression force of 12–18 kN, producing tablets with a hardness of 5–8 kp and a friability of ≤0.8%. The compendial test is USP <711> with Apparatus 2 at 75 rpm in 900 mL of 1% sodium lauryl sulfate; the acceptance criterion is NLT 75% released at 60 min. Uniformity of dosage units is assessed by USP <905> with an acceptance value of ≤15.0. Residual solvent compliance follows ICH Q3C for the binder solvent if a hydroalcoholic granulation is substituted, but direct compression avoids solvent exposure entirely. The finished immediate-release tablet is labelled at 100 mg, 200 mg, or 400 mg and is typically packed in HDPE bottles with a desiccant because storage above 25°C and 60% RH accelerates surface recrystallisation of the dihydrate phase.

What limits the formulation latitude for extended-release carbamazepine matrices?

The principal constraint is the API's low aqueous solubility, which makes release from a hydrophilic matrix sensitive to polymer hydration rate, ionic strength of the dissolution medium, and tablet-to-tablet density variation. A 200 mg extended-release matrix core with a total mass of 350–450 mg uses carbamazepine at 45–57% w/w. Hydroxypropyl methylcellulose K15M is incorporated at 25–40% w/w as the release-controlling polymer. Lactose monohydrate or dibasic calcium phosphate dihydrate at 10–20% w/w provides compressibility; colloidal silicon dioxide at 0.5–1.0% w/w improves powder flow, and magnesium stearate is held at 0.5–1.0% w/w. Direct compression is preferred because wet granulation introduces free water that can convert anhydrous carbamazepine to the dihydrate inside the matrix, shifting both the porosity and the dissolution front. If dry granulation is required, roller compaction with a roll pressure of 4–8 MPa and a mill screen size of 0.8–1.2 mm preserves polymorph stability. Tablets are compressed at 25–35 kN to a hardness of 10–20 kp; excessive hardness closes the matrix and delays release beyond the 12-hour target, while insufficient hardness causes dose dumping in the first hour. The matrix must also pass the alcohol dose-dumping assessment described in the FDA guidance for extended-release oral dosage forms, using 0.1 N HCl with 5%, 20%, and 40% ethanol. Compendial testing under USP <711> typically requires a multi-point release specification covering 1 h, 4 h, 8 h, and 12 h in a surfactant-containing medium. Content uniformity follows USP <905> and dissolution acceptance ranges are tighter at the early time point than at the terminal time point to control burst release. The finished extended-release tablet is labelled at 100 mg, 200 mg, or 400 mg; it must not be split or crushed because the matrix structure controls the release-rate and a broken tablet can release the entire dose over 30–60 minutes.

Because extended-release capsules distribute carbamazepine across multiple bead populations, regulatory submissions require separate dissolution acceptance ranges for the immediate-release portion and the extended-release portion. One established approach uses three bead populations: an uncoated immediate-release bead, a lightly coated delayed-release bead, and a thicker-coated extended-release bead combined in a hard gelatin capsule shell of size 1 or 2. Drug layering onto sugar spheres of 0.5–0.6 mm diameter is carried out in a Wurster fluid bed with a bottom-spray insert. The layering dispersion contains carbamazepine suspended in an aqueous hydroxypropyl methylcellulose solution at 5–10% w/w; the drug content in the layered bead is typically 20–30% w/w of the finished bead mass. Sugar spheres constitute 60–75% w/w of the final bead. Ethylcellulose aqueous dispersion or an organic ethylcellulose system is applied at 8–15% w/w for functional coating, with triethyl citrate or dibutyl sebacate as plasticiser at 10–20% of polymer solids. Talc is included at 30–50% of polymer solids as an anti-tack agent. Coating thickness is monitored by cumulative weight gain and by dissolution release of a marker bead batch; weight gain is not a sufficient control because atomisation efficiency shifts with inlet air temperature and spray rate. Fluid bed product temperature is maintained below 40°C during drug layering to avoid conversion of the anhydrous form to the dihydrate. After coating, the beads are dried at 40–50°C for 2–4 hours. Dissolution testing uses USP <711> Apparatus 1 at 100 rpm with a multi-point specification in a surfactant-containing acidic medium; separate acceptance criteria are set for the immediate-release fraction and the extended-release fraction because the combined release curve can mask failure of one bead population. Capsule filling on an automatic capsule machine is controlled for fill weight, particle size distribution, and bead friability; excessive bead breakage during filling creates fines that accelerate release. The finished capsule is labelled at 100 mg, 200 mg, or 300 mg and must not be opened or sprinkled on soft food unless the monograph permits because bead crushing alters the release profile.

When paediatric dosing demands a stable carbamazepine granule for reconstitution

Aqueous granulation is excluded from this granule line because contact with free water during massing converts the API to the dihydrate, altering dissolution. Dry roller compaction followed by sieving to a granule size of 0.5–1.5 mm is used to preserve the anhydrous polymorph. The granule blend for an oral suspension delivering 100 mg/5 mL after reconstitution contains carbamazepine at 10–20% w/w of the dry granule mass. Sucrose or a sucrose-mannitol co-filler at 70–85% w/w provides bulk density and palatability. Xanthan gum at 1–3% w/w is dry-blended as the suspending agent; if prehydrated before blending, it forms a gel that resists uniform distribution. Microcrystalline cellulose at 5–10% w/w improves granule compactibility. Sodium saccharin or sucralose at 0.1–0.5% w/w masks the bitter taste. The dry granule is filled into amber glass or HDPE bottles with a desiccant closure. Reconstitution with purified water to the graduated mark produces a suspension with a sedimentation volume of 0.7–0.9 after 24 hours, but the product must be shaken before each dose. The compendial requirement for oral suspension is not disintegration but assay and uniformity; USP <905> is applied to the reconstituted suspension after shaking. Microbiological quality follows USP <61> and USP <62>. The reconstituted suspension is stored at controlled room temperature below 25°C; published stability data for this specific granule configuration is limited, so a use period of 30 days is assigned only after an in-use stability protocol is completed under ICH Q1A(R2).

Injectable carbamazepine and the solubility barrier of anhydrous Form III

Injectable presentation remains confined to investigational and compounded preparations because carbamazepine's reported aqueous solubility at 25°C is approximately 0.12 mg/mL, which is below the concentration required for a practical parenteral dose of 10 mg/mL. Co-solvent systems containing propylene glycol at 20–30% v/v, ethanol at 10–20% v/v, and water for injection at 50–70% v/v have been evaluated for solubility enhancement. The terminal product must remain clear after dilution with 0.9% sodium chloride or 5% dextrose; precipitation can occur when the co-solvent concentration drops below 15–20% v/v during infusion. Sulfobutyl ether β-cyclodextrin at 20–30% w/v has been reported as an alternative complexing agent, but published production-scale data for this specific configuration is limited. The drug solution is sterile-filtered through a 0.22 µm polyvinylidene fluoride membrane; terminal steam sterilisation at 121°C is generally avoided because the anhydrous polymorph may convert to the dihydrate or degrade, and published thermal stability data in the co-solvent matrix are limited. Particulate matter is controlled by USP <788> for small-volume injections; visible particles are assessed by USP <790>. Osmolality is adjusted to 270–330 mOsm/kg if the preparation is administered by intravenous infusion. The injectable product is not a commercial carbamazepine dosage form in most pharmacopoeias; therefore compendial monograph support is not established and each compounded batch requires a validated stability protocol under ICH Q1A(R2). The practical injection is extemporaneously prepared, labelled with a short beyond-use date, and administered through a low-protein-binding filter to reduce particulate burden.

When swallowing is impaired, carbamazepine is delivered as a chewable tablet with a target hardness between 3.0 and 6.0 kp. A 100 mg chewable tablet with a core mass of 500–700 mg places the drug load at 14–20% w/w. Mannitol at 40–60% w/w provides sweetness, a negative heat of solution, and sufficient compactibility. Microcrystalline cellulose at 10–15% w/w acts as a binder and texturiser. Crospovidone at 3–6% w/w is selected over croscarmellose sodium because it gives rapid wetting without a pronounced gelling sensation. Sodium saccharin, aspartame, or sucralose at 0.1–0.5% w/w mask the bitter taste; a cooling flavour is incorporated at 0.2–0.8% w/w. Magnesium stearate is limited to 1.0–2.0% w/w because higher levels reduce tablet hardness below the compressibility threshold. Direct compression at 10–15 kN yields tablets with friability below 1.0%. Chewable tablets are not required to meet a disintegration standard if they are chewed before swallowing, but dissolution is assessed by USP <711> using a surfactant-containing medium; the acceptance criterion reflects the intended chewed delivery rather than an intact tablet pathway. The finished chewable tablet is labelled at 100 mg and is packed in unit-dose blisters to limit moisture ingress, because the mannitol phase can soften above 60% RH.